Previous Article | Next Article ![]()
Journal of Virology, April 2000, p. 3668-3681, Vol. 74, No. 8
Departments of Microbiology & Immunology and
Medicine, UCLA School of Medicine, Los Angeles, California
90095-1678
Received 7 September 1999/Accepted 19 January 2000
We constructed human immunodeficiency virus type 1 (HIV-1) vectors
that will allow higher levels of gene expression in T cells. Gene
expression under the control of an internal cytomegalovirus (CMV)
immediate-early promoter in a self-inactivating lentiviral vector
(CSCG) is 4- to 15-fold lower in T-cell lines (SUPT1 and CEMX174) than
in non-lymphoid-cell lines (HeLa and 293T). This is in contrast to a
Moloney murine leukemia virus (MoMLV)-based retrovirus vector
(SR
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
A Murine Leukemia Virus (MuLV) Long Terminal Repeat Derived from
Rhesus Macaques in the Context of a Lentivirus Vector and MuLV
gag Sequence Results in High-Level Gene Expression in
Human T Lymphocytes
LEGFP). We therefore replaced the internal CMV promoter of CSCG
with three different murine oncoretroviral long terminal repeat (LTR)
promoters
murine sarcoma virus (MSV), MoMLV (MLV), and the LTR (termed
Rh-MLV) that is derived from the ampho-mink cell focus-forming
(AMP/MCF) retrovirus in the serum of one rhesus macaque monkey that
developed T-cell lymphoma following autologous transplantation of
enriched bone marrow stem cells transduced with a retrovirus vector
preparation containing replication-competent viruses (E. F. Vanin,
M. Kaloss, C. Broscius, and A. W. Nienhuis, J. Virol.
68:4241-4250, 1994). We found that the combination of Rh-MLV LTR and a
partial gag sequence of MoMLV (
gag871-1612) in CS-Rh-MLV-E gave the
highest level of enhanced green fluorescent protein (EGFP) gene
expression compared with MLV, MSV LTR, phosphoglycerate kinase, and CMV
promoters in T-cell lines, as well as activated primary T cells.
Interestingly, there was a further two- to threefold increase in EGFP
expression (thus, 10-fold-higher expression than with CMV) when the
Rh-MLV promoter and
gag871-1612 were used
in a self-inactivating-vector setting that has a further deletion in
the U3 region of the HIV-1 LTR. These hybrid vectors should prove
useful in gene therapy applications for T cells.
*
Corresponding author. Mailing address: Departments of
Microbiology & Immunology and Medicine, UCLA School of Medicine, 10833 Le Conte Ave., 11-934 Factor Building, Los Angeles, CA 90095-1678. Phone: (310) 825-4793. Fax: (310) 794-7682. E-mail:
rtaweesu{at}ucla.edu.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»